Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC - A randomized phase III trial

Journal of Clinical Oncology

Volumn 34, Issue 5, 2016, Pages 443-451

  Hecht, J Randolph ^a   Bang, Yung Jue ^c   Qin, Shukui K ^f   Chung, Hyun C ^d   Xu, Jianming M ^g   Park, Joon O ^e   Jeziorski, Krzysztof ⁱ   Shparyk, Yaroslav ^j   Hoff, Paulo M ^k   Sobrero, Alberto ^l   Salman, Pamela ^m   Li, Jin ^h   Protsenko, Svetlana A ⁿ   Wainberg, Zev A ^a   Buyse, Marc ^o   Afenjar, Karen ^p   Houè, Vincent ^p   Garcia, Agathe ^p   Kaneko, Tomomi ^q   Huang, Yingjie ^r   Khan Wasti, Saba ^q   Santillana, Sergio ^r   Press, Michael F ^b   Slamon, Dennis ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Seoul National University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Samsung Medical Center   (South Korea)

^f Nanjing Bayi Hospital   (China)

^g BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^h FUDAN UNIVERSITY   (China)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j Chemotherapy Department   (Ukraine)

^k Sociedade Beneficente de Senhoras Hospital Sirio Liba s   (Brazil)

^l UNIVERSITY OF GENOA   (Italy)

^m Centro Oncológico Fundación Arturo López Pérez   (Chile)

ⁿ N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^o INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^p Translational Research in Oncology (TRIO)   (France)

^q GLAXOSMITHKLINE   (United Kingdom)

^r GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CAPECITABINE; ERBB2 PROTEIN, HUMAN; OXALIPLATIN; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; ASIAN; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; EVENING DOSAGE; FATIGUE; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; GENETICS; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CAPECITABINE; DOUBLE-BLIND METHOD; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84958818670     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.6598     Document Type: Article

References (24)

1. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods andmajor patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
2. Wagner AD, Unverzagt S, Grothe W, et al: Chemotherapy for advanced gastric cancer. Cochrane Database of Syst Rev 3:CD004064, 2010
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006
4. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976, 2011
5. Cunningham D, Okines AF, Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362:858-859, 2010
6. Allgayer H, Babic R, Gruetzner KU, et al: CerbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18:2201-2209, 2000
7. Deng N, Goh LK, Wang H, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684, 2012
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
9. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
10. Zheng J, de Guia T, Wang-Jairaj J, et al: Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: A randomised placebo-controlled trial. Curr Med Res Opin 31:1191-1200, 2015
11. Wainberg ZA, Anghel A, Desai AJ, et al: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509-1519, 2010
12. Iqbal S, Goldman B, Fenoglio-Preiser CM, et al: Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22:2610-2615, 2011
13. Wielders PL, Ludwig-Sengpiel A, Locantore N, et al: A new class of bronchodilator improves lung function in COPD: A trial with GSK961081. Eur Respir J 42:972-981, 2013
14. Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 23:932-946, 2004
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Press MF, Finn RS, Cameron D, et al: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861-7870, 2008
17. Common Terminology Criteria for Adverse Events v3.0 (CTCAE): http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf
18. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
19. Gelmon KA, Boyle F, Kaufman B, et al: Openlabel phase III randomized controlled trial comparing taxane-based chemotherapy (Tax)with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30, 2012 (suppl; abstr LBA671)
20. Koch KM, Reddy NJ, Cohen RB, et al: Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 27: 1191-1196, 2009
21. Satoh T, Rui-Hua X, Chung HC, et al: Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN, a randomized, phase III study. J Clin Oncol 32: 2039-2049, 2014
22. Gill S, Shah A, Le N, et al: Asian ethnicityrelated differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J Clin Oncol 21:2070-2976, 2003
23. Tan IB, Ivanova T, Lim KH, et al: Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141:476-485, 485.e1-485.e11, 2011
24. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014